Navigation Links
Sanofi Announces Positive Phase 3 Results for Investigational New Insulin U300
Date:6/22/2013

PARIS, June 22, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection). The company also announced topline results of a second Phase 3 study (EDITION II) for new insulin U300 that also demonstrated similar blood sugar reduction while fewer patients experienced night-time low blood sugar events compared with Lantus®.

(Logo: http://photos.prnewswire.com/prnh/20110624/NY25833LOGO )

These results are from EDITION I and EDITION II respectively and are part of the EDITION Phase 3 clinical program evaluating the efficacy and safety of the investigational new insulin U300 in people with diabetes.  The EDITION I data was presented at the 73rd Scientific Sessions of the American Diabetes Association.

"To properly manage diabetes, it is critical to control blood sugar and to reduce the risk of low blood sugar events, especially at night," said Matthew Riddle, Professor of Medicine, Division of Endocrinology/Diabetes/Clinical Nutrition, Oregon Health and Science University, U.S., and Principal Investigator for the EDITION I study. "I am encouraged by these findings, and look forward to the results of the full Phase 3 EDITION program, which will further reveal how this investigational basal insulin may help people living with diabetes."

EDITION IAs the first study of the EDITION Phase 3 program, EDITION I evaluated the efficacy and safety of investigational new insulin U300, vs. Lantus® in people with type 2 diabetes using basal pl
'/>"/>

SOURCE Sanofi
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi Announces Positive Phase 3 Data for Once-Daily Lixisenatide for Type 2 Diabetes
2. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
3. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
4. The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
5. Sanofi and Regeneron Announce Patient Enrollment in Two Phase 3 Trials with Sarilumab in Rheumatoid Arthritis (RA)
6. Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol)
7. NextBio Announces Translational Medicine Partnership with Sanofi
8. Hemodialysis Patient Share for Sanofis Ferrlecit Increased Significantly in the First Quarter of 2013 Compared to the Previous Quarter
9. Sanofi US Offers a New Way to Say "Thank You" and Recognize the Unsung Heroes of Severe Allergy Awareness
10. Sanofi and Regeneron Report Positive Proof-of-Concept Data for Dupilumab, an IL-4R alpha Antibody, in Atopic Dermatitis
11. Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... and VANCOUVER , July 30, ... announced today that it will report its second quarter ... management will host a conference call and live webcast ... of financial results, clinical development programs and a general ... log on to the Investor Relations page of the ...
(Date:7/30/2015)... 30, 2015  Cleveland Clinic President Wael Barsoum ... last month that industry is compelled to adopt declining ... the efficiencies—and develop the transformational innovations -- required to ... were preceded by Doug Kohrs , past President ... who stressed that industry must add "episode of care," ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Orthopaedic Surgery Reimbursement Shifts to Episode of Care 2
... 2011 Aprima Medical Software announced today the acquisition ... Revenue Cycle Management (RCM) services to physician offices throughout ... receivables collection rates and days sales outstanding (DSO) for ... improvement in DSOs vs. industry standards. Aprima ...
... Aug. 10, 2011 Northwest Biotherapeutics (OTC.BB: NWBO) reminded ... Provenge immune therapy, that NWBT,s DCVax® immune therapies for ... and others) hold the promise, based on available data ... other immune therapies while still providing substantial profit margins ...
Cached Medicine Technology:Aprima and Health Care Strategies Join Forces to Improve the Financial Health of Physicians 2Aprima and Health Care Strategies Join Forces to Improve the Financial Health of Physicians 3NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns 2NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns 3NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns 4NWBT Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns 5
(Date:8/1/2015)... NY (PRWEB) , ... August 01, 2015 , ... On ... cyberespionage group , who are thought to have been behind the attack on Anthem ... topics covered were zero day exploits, watering hole attacks and spear phishing campaigns. ...
(Date:8/1/2015)... ... , ... On March 19, 2015 Phil Valentine – the Executive Director of Connecticut Community for ... by stepping off Springer Mountain and heading north. Since that day, Phil has hiked over ... was greeted by friends and family. He visited CCAR and left an inspirational message ...
(Date:7/31/2015)... ... ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened a ... July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and Latin ... Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department of ...
(Date:7/31/2015)... ... 2015 , ... Recently touted by Becker’s Healthcare as one ... , Jvion continues to disrupt the predictive analytic and big data market using ... population level illness to drive prevention and better health outcomes. Most recently, Jvion ...
(Date:7/31/2015)... ... 2015 , ... There’s no better way to enjoy the summer weather than ... the next meal, making July the most appropriate to be National Hot Dog Month. ... , Make the next cookout different than the ones in the past. Celebrate National ...
Breaking Medicine News(10 mins):Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 2Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 3Health News:Frenemy at the Gates - Hackers Excel at Leveraging Trust 4Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 2Health News:King Kullen Honors National Hot Dog and Blueberry Month 3
... Record Quarterly Revenue of $48.6 Million ... Reaches Record Level of $642 Million, SUNNYVALE, Calif., Nov. ... in the field of radiosurgery,today announced financial results for the ... the first quarter of fiscal 2008, Accuray reported record total,revenue ...
... OAKLAND, Calif., Nov. 7 Kaiser Foundation Health ... reported,total operating revenue for the third quarter ending ... $8.7 billion in the same period last year. ... was $449 million, as,compared with $355 million during ...
... in AML, NEW HAVEN, Conn., Nov. 7 ... the three-month and nine-month periods ended September 30, 2007. ... million, or $0.13 per share,for the three-month period ended ... million, or $0.10 per share, for the same period ...
... 4:30 p.m. EST http://www.westaim.com , CALGARY, Nov. ... at 4:30 p.m. EST on Tuesday, November 13, 2007 ... to standard disclosure over wire services, a news release,and ... site. To listen,to the call live on the Internet, ...
... CHICAGO, Nov. 7 U.S. Environmental,Protection Agency Region ... American Lung,Association of Indiana for a community-based initiative ... while promoting indoor air,quality and healthy schools in ... "EPA is concerned about the health and ...
... Activism, Cancer Group Partnerships and Bi-Partisan Support Key ... of Landmark Cancer Research Legislation, DALLAS, Nov. 7 ... Affiliates, commends Texas voters for passing Proposition,15, bringing $3 billion ... leader in the cancer movement. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ...
Cached Medicine News:Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 2Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 3Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 4Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 5Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 6Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 7Health News:Accuray Reports Record Revenue in First Quarter of Fiscal 2008 8Health News:Kaiser Foundation Health Plan Earnings Support Investments in Member and Community Health 2Health News:Kaiser Foundation Health Plan Earnings Support Investments in Member and Community Health 3Health News:Kaiser Foundation Health Plan Earnings Support Investments in Member and Community Health 4Health News:Vion Reports 2007 Third Quarter and Nine-Month Results 2Health News:Vion Reports 2007 Third Quarter and Nine-Month Results 3Health News:Vion Reports 2007 Third Quarter and Nine-Month Results 4Health News:Vion Reports 2007 Third Quarter and Nine-Month Results 5Health News:Vion Reports 2007 Third Quarter and Nine-Month Results 6Health News:EPA Awards Grant to American Lung Association of Indiana for Community Environmental Health Initiative 2Health News:Susan G. Komen for the Cure Celebrates Passage of Proposition 15 2
... that suppress the secretion of FSH (follicle ... of two distinct chains, or subunits (alpha ... of the alpha-subunit and betaA-subunit. Inhibin B ... the dimeric forms of the molecule, containing ...
... factor II (IGF-II) is a 7.5 kDa peptide ... is postulated to have mitogenic and metabolic actions ... are mediated by binding to target cell receptors. ... II IGF receptor, a monomeric protein which also ...
... A (PAPP-A) is a large placenta-derived ... high concentrations by placental trophoblast cells, ... circulation in increasing concentrations throughout gestation ... specific to pregnancy since measurable levels ...
... weight of 16 kDa. Leptin is a protein ... [1,2]. Leptin is thought to play a key ... In the human, leptin levels are elevated with increasing ... relationship between serum leptin levels and several measures of ...
Medicine Products: